Hookworm Infection Clinical Trial
Official title:
Efficacy and Nutritional Assessment Following Albendazole and Combined Albendazole/Ivermectin Treatment for Intestinal Helminth Infections in Rural Guatemalan Schoolchildren
The aim of this study is to compare the efficacy and impact on growth of two drug treatments against intestinal worms in schoolchildren from a rural area of Guatemala. According to the World Bank, these intestinal worms are one of the top causes of childhood health problems in many areas of the developing world (The World Bank, 1993). Infected children are more likely to have inadequate nutrition due to the worm infections and are more likely to be shorter in height and weigh less than children who are not infected. After collecting height and weight information, we will split the children into two groups. One group will receive albendazole and the other group will receive combined albendazole/ivermectin. Both groups will be receiving albendazole, the current standard of care treatment. Ivermection is expected to improve efficacy and nutritional benefit as well as add increased scope of treatment for the worm Strongyloides, and ectoparasites such as scabies and head lice. Both treatment regimens and the combination have been used millions of times in the developing world and are safe to use. Co-administration of drugs would be a more efficient use of the opportunity to access schoolchildren and provide deworming treatment.
The aim of this study is to compare the efficacy and nutritional impact of two drug
treatments against intestinal helminths from a rural area of Guatemala. The helminths that
will be analyzed in this study are Ascaris lumbricoides, Trichuris trichiura, and hookworm.
Because of the manifestations of these helminths infections, nutritional status can
deteriorate in infected persons. According to the World Bank, these helminths are one of the
top causes of childhood morbidity in many areas of the developing world (The World Bank,
1993).
This information will be gathered by collecting stool samples from schoolchildren, in order
to determine the prevalence of infection in children living around Poptun, Guatemala. Height
and weight measurements will also be taken, along with a visual exam of the skin for other
parasitic skin infections. Children with an inadequate nutritional status are likely to be
shorter in height and weigh less than children reared in an area with a low prevalence of
helminths. After collecting this baseline information, we will split the children into two
groups. One group will receive albendazole and the other group will receive
albendazole/ivermectin. Both groups will be receiving is albendazole, the current standard
of care treatment. Ivermectin is expected to improve efficacy and nutritional benefit as
well as adding increased scope of treatment (Strongyloides, ectoparasites such as scabies
and head lice). Both treatment regimens and the combination have been used millions of times
in the developing world and are safe to use. Co-administration of drugs is thought to be a
more efficient use of the opportunity to access schoolchildren and provide health
improvements. Providing data to support expanded treatment options will provide public
health officials with the data needed to make such decisions.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03278431 -
Triple Combinations Against Hookworm Infections in Lao
|
Phase 4 | |
Completed |
NCT01717950 -
Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults
|
Phase 1 | |
Completed |
NCT02143518 -
Safety and Immunogenicity Study of Na-GST-1 With or Without CpG
|
Phase 1 | |
Completed |
NCT02126462 -
Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults
|
Phase 1 | |
Completed |
NCT01261130 -
Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With or Without Additional Adjuvant in Brazilian Adults
|
Phase 1 | |
Completed |
NCT01385189 -
Safety and Immunogenicity of a Human Hookworm Candidate Vaccine With Different Doses of a Novel Adjuvant
|
Phase 1 | |
Terminated |
NCT00473967 -
Phase 1 Trial of Na-ASP-2 Hookworm Vaccine in Previously Infected Brazilian Adults
|
Phase 1 | |
Completed |
NCT00603889 -
Development of a Skin Test for the Na-ASP-2 Hookworm Antigen
|
N/A | |
Completed |
NCT02839161 -
Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children
|
Phase 1 | |
Completed |
NCT02476773 -
Study of Na-APR-1 (M74)/Alhydrogel® Co-administered With Na-GST-1/Alhydrogel in Brazilian Adults
|
Phase 1 | |
Recruiting |
NCT01940757 -
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
|
Phase 1 | |
Completed |
NCT03373214 -
Na-GST-1/Alhydrogel With or Without CpG 10104 in Gabonese Adults
|
Phase 1 | |
Completed |
NCT00939198 -
Prevalence of Hookworm Infection and Community Preparedness for Hookworm Vaccine Trials in Endemic Areas of Brazil
|
N/A | |
Active, not recruiting |
NCT02262403 -
Hookworm Immune Regulation Project
|
N/A | |
Completed |
NCT00120081 -
Study of Na-ASP-2 Human Hookworm Vaccine in Healthy Adults Without Evidence of Hookworm Infection
|
Phase 1 | |
Recruiting |
NCT05914363 -
Evaluating Impact of Improved Floors on Health
|
N/A |